Aliskiren Hemifumarate - CAS 173334-58-2
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Aliskiren Hemifumarate
Catalog Number:
B0084-060956
Synonyms:
Aliskiren fumarate; Aliskiren (hemifumarate); UNII-C8A0P8G029; CHEBI:53777
CAS Number:
173334-58-2
Description:
Aliskiren hemifumarate is an orally bioactive renin inhibitor (human IC50 = 0.6 nM; rat IC50 = 80 nM) appearing to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site towards the hydrophobic core of renin. It exhibits an inhibitory activity for arterial vasoconstriction and aldosterone production.
Molecular Weight:
1219.61
Molecular Formula:
C64H110N6O16
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N.CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N.C(=CC(=O)O)C(=O)O
InChI:
InChI=1S/2C30H53N3O6.C4H4O4/c2*1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36;5-3(6)1-2-4(7)8/h2*10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35);1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*22-,23-,24-,25-;/m00./s1
InChIKey:
KLRSDBSKUSSCGU-KRQUFFFQSA-N
Targets:
Renin
Chemical Structure
CAS 173334-58-2 Aliskiren Hemifumarate

Related Renin Products


CAS 1264191-73-2 VTP-27999 Hydrochloride

VTP-27999 Hydrochloride
(CAS: 1264191-73-2)

VTP-27999 Hcl is an alkyl amine Renin inhibitor; VTP-27999 is useful for Hypertension and End-Organ Diseases.

PD 125967
(CAS: 128139-14-0)

PD 125967 is a renin inhibitor which may be useful for treatment of essential hypertension.

CAS 173334-57-1 Aliskiren

Aliskiren
(CAS: 173334-57-1)

Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site tow...

CAS 173334-58-2 Aliskiren Hemifumarate

Aliskiren Hemifumarate
(CAS: 173334-58-2)

Aliskiren hemifumarate is an orally bioactive renin inhibitor (human IC50 = 0.6 nM; rat IC50 = 80 nM) appearing to bind to both the hydrophobic S1/S3-binding po...

PD 125754
(CAS: 124339-32-8)

This active molecular is a Renin inhibitor that applicated in treatment of essential hypertension.

CP 84364
(CAS: 114457-62-4)

CP 84364 is an active metabolite of CP-80794 which is a Renin inhibitor.

CAS 942142-51-0 VTP-27999

VTP-27999
(CAS: 942142-51-0)

VTP-27999 is an alkyl amine Renin inhibitor. It is useful for Hypertension and End-Organ Diseases.

CAS 1013937-63-7 VTP-27999 2,2,2-trifluoroacetate

VTP-27999 2,2,2-trifluoroacetate
(CAS: 1013937-63-7)

VTP-27999 2,2,2-trifluoroacetate is an alkyl amine Renin inhibitor, useful for Hypertension and End-Organ Diseases.

CI 992
(CAS: 135704-06-2)

CI 992 is a renin inhibitor originated by Pfizer. Preclinical trials for Hypertension in USA was discontinued in 1994.

PD 132002
(CAS: 134452-04-3)

PD 132002 is a renin inhibitor originated by Pfizer. In Dec 2001, clinical trials for Hypertension in USA was discontinued.

CAS 126222-34-2 Remikiren

Remikiren
(CAS: 126222-34-2)

Remikiren is a renin inhibitor originated by Roche in 1996. But clinical trials for the treatment of Heart failure and Hypertension was discontinued.

CAS 1246815-96-2 Aliskiren D6 Hydrochloride

Aliskiren D6 Hydrochloride
(CAS: 1246815-96-2)

An orally active, labelled synthetic nonpeptide renin inhibitor. Antihypertensive.

Reference Reading


1. Simultaneous Determination of Aliskiren, Amlodipine and Hydrochlorothiazide in Spiked Human Plasma and Urine by High Performance Liquid Chromatography
Zeynep Aydomugs. Journal of Analytical Chemistry, 2015, Vol. 70, No. 4, pp. 502–509.
Aliskiren hemifumarate (Scheme) is the direct rennin enzyme inhibitor clinically used in treatment of hypertension either alone or in combination with other antihypertensive agents. After administration, ALS is rapid ly absorbed with peak plasma concentration occurring after 1–3 h. Its bioavailability is about 2.6% and it is eliminated unchanged primarily by the biliary-fecal route (91%) and renal excretion is only about 0.6%.
2. Ion‑Pair LC Method for Simultaneous Determination of Aliskiren Hemifumarate, Amlodipine Besylate and Hydrochlorothiazide in Pharmaceuticals
Ramzia I. El‑Bagary • Gabor Patonay • Asmaa A. Elzahr • Ehab F. Elkady • Walid A. Ebeid. Chromatographia (2014) 77:257–264
Aliskiren hemifumarate (ALS) (2S,4S,5S,7S)-N-(2-carba-moyl-2-methylpropyl)-5-amino-4-hydroxy-2,7 diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy) phenyl]octanamide hemifumarate) (Fig. 1a), is the first direct renin inhibitor (DRI) suitable for oral administration. By achieving more complete renin–angiotensin system inhibition, direct renin inhibitors may afford greater protection from hypertensive complications. Present evidence indicates that aliskiren reduces baseline systolic and diastolic blood pressure and that it is as effective as other first-line anti-hypertensive agents. Extra advantages can be reached when it is used in combination therapy. Amlodipine besylate (AML) (3-ethyl-5-methyl-(4RS)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulfonate) (Fig. 1b), is a dihydropyridine long-acting calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure. Hydrochlorothiazide is a potent orally diuretic and anti-hypertensive agent which inhibits active chloride reabsorption and thus increases the excretion of sodium chloride and water. It is chemically 6-chloro-1,1-dichloro-3,4-dihydro-2H-1,2,4-benzoliadiazine-7-sulfanomide-1,1-dioxide (Fig. 1c). Triple combination therapy of Aliskiren hemifumarate (ALS), AML and HCZ proved to be effective and well tolerated in treating hypertensive high-risk patients.